Gasdermin D Antibody [B17C12]

Catalog No.: F4764

    Application: Reactivity:
    • Lane 1: THP-1 (TPA, 50 ng/mL, 24 h; rested 48 h), Lane 2: THP-1 (TPA, 50 ng/mL, 24 h; rested 48 h; LPS, 5 μg/mL, 6 h)
    1/

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    使用情報

    Dilution
    1:1000
    1:50
    1:50
    1:800 - 1:1600
    Application
    WB, IP, IHC, IF
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Human
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    53 kDa 53 kDa, 30 kDa
    *なぜ予測分子量と実際の分子量が異なるのか?
    下記の原因により、実際の分子量が予測と異なる:タンパク質の翻訳後修飾(リン酸化/糖鎖付加),スプライシングバリアント,イソフォーム,相対的な電荷,ポリマー。

    Datasheet & SDS

    生物学的記述

    Specificity
    Gasdermin D Antibody [B17C12] detects endogenous levels of total Gasdermin D protein.
    Clone
    B17C12
    Synonym(s)
    DF5L; DFNA5L; FKSG10; FLJ12150; gasdermin D; Gasdermin-D; Gasdermin-D, C-terminal; Gasdermin-D, N-terminal; GSDMD; GSDMD-CT; GSDMD-NT; GSDMDC1
    Background
    Gasdermin D (GSDMD) is a pore-forming member of the gasdermin family that functions as the central executioner of inflammasome-dependent pyroptosis and links inflammatory caspase activity to membrane rupture and cytokine release. The protein contains an N-terminal effector domain with intrinsic membrane-perforating capacity and a C-terminal autoinhibitory domain joined by a linker that carries the conserved caspase cleavage site, and this arrangement maintains GSDMD in a latent conformation until site-specific proteolysis occurs. Canonical and noncanonical inflammasomes activate caspase-1 and caspase-4/5/11, which cleave the linker to liberate the N-terminal fragment from C-terminal restraint, allowing the N-terminus to translocate to phospholipid-rich membranes and initiate pyroptotic execution. The liberated N-terminal fragment binds acidic phospholipids in the inner leaflet of the plasma membrane and other cellular membranes, oligomerizes into large ring-like complexes, and assembles variable-sized pores that disrupt ionic balance, drive water influx, and generate the characteristic swelling and lytic rupture of pyroptotic cell death. These pores provide conduits for unconventional secretion of mature interleukin-1 family cytokines, including IL-1β and IL-18, and allow the release of alarmins and intracellular contents that amplify local and systemic inflammation. Structural and biochemical analyses place cysteine residues and defined interface surfaces in the N-terminal domain as critical modulators of oligomerization and pore architecture, while the C-terminal region contributes interaction motifs that stabilize the inactive state and may integrate upstream regulatory inputs. GSDMD activity intersects with membrane repair, lipid composition, and post-translational modifications, which collectively determine the number, stability, and localization of pores and thereby tune whether cells undergo full lysis or primarily secrete cytokines through a partially preserved plasma membrane. GSDMD-mediated pore formation contributes to pathogen clearance, inflammasome-driven cytokine signaling, and neutrophil effector mechanisms, while dysregulated or sustained activation drives tissue damage and chronic inflammation in diverse organs. Aberrant GSDMD activation is linked to inflammatory diseases of the cardiovascular system, liver, pancreas, and other tissues, where excessive pyroptosis and cytokine release promote persistent inflammatory microenvironments and organ dysfunction.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください